Articles

Videos

Podcasts

Clinical

A researcher discusses how developing tertiary lymphoid structures may reach a greater maturity level within the tumor microenvironment.

Tertiary Lymphoid Structure May Improve Immunity for Patients With Ovarian Cancer

Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

FDA Approves Bevacizumab Biosimilar for Six Types of Cancer

Selpercatinib produced clinically meaningful and durable responses across a variety of tumor types in patients with RET-driven cancers.

FDA Approves Selpercatinib for Advanced, Metastatic Solid Tumors With RET Gene Fusion

AstraZeneca’s Lynparza in combination or as a monotherapy demonstrates meaningful survival benefit in long-term follow-up.

Olaparib With or Without Bevacizumab Shows Positive Results as Ovarian Cancer Treatment

Research suggests that rucaparib can increase progression-free survival by more than a year in women with advanced ovarian cancer.

Clovis Oncology Submits New Drug Application for Rucaparib as First-Line Maintenance Treatment for Advanced Ovarian Cancer

New results presented at the 2022 ESMO conference reinforce the potential of rucaparib as a first-line maintenance treatment option in a broad population of patients with ovarian cancer.

Study: Rucaparib Improves Progression-Free Survival as First-Line Maintenance Therapy in Advanced Ovarian Cancer

Women at high risk for breast and ovarian cancer felt less worried and better informed with educational intervention, even if their attendance of genetic counseling did not significantly increase.

Study Finds Genetic Counseling for Breast, Ovarian Cancer Syndrome Did Not Significantly Increase with Clinician Support

Rucaparib (Rubraca) is a poly (ADP-ribose) polymerase (PARP) inhibitor used for ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and castration-resistant prostate cancer.

Daily Medication Pearl: Rucaparib (Rubraca)

Christine Walko, PharmD, BCOP, FCCP, discusses some new developments for PARP inhibitors in cancer care for patients with homologous recombination deficiency.

Expert: ‘Our Understanding of Homologous Recombination Deficiency Is Evolving’ in Oncology Pharmacy Field

Folate receptor α may be an important treatment target for ovarian tumors.

Current Standards of Care in Platinum-Resistant Ovarian Cancer

® Ovarian Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to the group of diseases that originates in the ovaries, fallopian tubes, or the peritoneum.